Are GPs Now Prescribing Mounjaro for Weight Loss?

You've asked your GP about Mounjaro and got a vague answer. Here's why.

If you've raised tirzepatide with your GP and been met with uncertainty, you're not alone. The situation genuinely is patchy. From 1 April 2026, GP practices in England gained the ability to prescribe Mounjaro for weight management under the updated QOF contract, but practices opted into this voluntarily. Some have embraced it; others haven't yet set up the necessary pathways, dietitian referrals or monitoring arrangements. A GP who says "we're not doing that yet" isn't wrong; they may simply be in a practice that hasn't mobilised.

When a practice does participate, the clinical bar is currently set at BMI ≥40 combined with four or more qualifying conditions from a defined list: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. From around June 2026, the second cohort opened access to people with BMI 35–39.9 meeting the same four-condition threshold. Lower BMI thresholds apply for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under NICE's tirzepatide appraisal (TA1026). These are not soft guidelines, they are the conditions under which NHS prescribing is commissioned.

Even where the criteria are met, every NHS patient must take part in structured wraparound support covering diet and physical activity. That's a clinical requirement, not an add-on. Meeting the criteria on paper doesn't guarantee a prescription; the prescriber still assesses the full picture. You can read more about how the GP prescribing pathway for tirzepatide operates in practice, including what the wraparound support involves.

What the NHS rollout doesn't cover, and where the gaps sit

The phased NHS rollout means most people asking about Mounjaro right now don't qualify. BMI 30–34.9 with a single comorbidity (the threshold at which tirzepatide is licensed as a medicine) sits well below the NHS commissioning threshold. Someone with a BMI of 32 and hypertension is clinically eligible for a private prescription under the terms of the SmPC, but currently falls outside NHS criteria entirely.

There's also the question of time. Even in practices that are prescribing, appointments need to be made, referrals arranged, dietitian capacity found. Waiting lists exist at every tier of the NHS. That's not a criticism; it's a resource reality. If you're in that position (eligible for the medicine but outside the NHS window) it's worth understanding what a private route actually involves. The routes to Mounjaro in the UK without an NHS referral cover that clearly. For context on how tirzepatide sits within the broader private treatment landscape, the cost context for Mounjaro in the UK is worth reading before you make any decisions.

Scotland, Wales and Northern Ireland operate different commissioning frameworks with different thresholds. If you're outside England, the specifics for your nation matter, your GP will know what's been commissioned locally.

Private prescribing: the same medicine, a different route

A private prescription for Mounjaro carries the same legal and clinical weight as an NHS one. The medicine is identical, sourced through the licensed UK supply chain from authorised Eli Lilly channels. The difference is who assesses you, who holds the clinical relationship, and how quickly that can happen.

At nume... wait, at nume, consultations are reviewed the same day by a GPhC-registered Independent Prescriber. A real clinician reads your answers, not software routing your form through an automated system. Identity is verified with photo ID; weight is confirmed on a live video call. If treatment is clinically appropriate, it's dispatched the same day for free next-working-day DPD delivery in plain packaging. There are no subscriptions and no auto-renewals; every repeat order goes through a clinical review before anything is sent.

The licensed private eligibility criteria are broader than the NHS thresholds: adults with BMI ≥30, or BMI ≥27 with at least one weight-related condition such as hypertension, high cholesterol, prediabetes or obstructive sleep apnoea. BMI alone never settles the question, the prescriber looks at the complete picture. For a fuller explanation of how tirzepatide works and what the clinical evidence shows, the tirzepatide overview is a good starting point, and the Mounjaro treatment page covers the UK specifics in detail.

It's worth knowing that Mounjaro carries a Black Triangle (▼) designation, meaning the MHRA collects additional safety data on it as a relatively new medicine. Side effects are real and worth understanding before you start, a summary of tirzepatide's side-effect profile can help you go into any consultation with the right questions.

If your GP practice isn't prescribing yet, what should you do?

Start by asking your practice directly whether they've enrolled in the new contract. Some haven't advertised it widely. If they haven't, you can ask whether a referral to a specialist weight management service is possible, that's the route that's existed for longer, and it may be available even where the new GP pathway isn't active.

If you want to move faster, or if you're in the majority who don't currently meet NHS thresholds, a consultation with a private GPhC-registered prescriber is a straightforward next step. There's no referral required, no waiting list, and the clinical review happens the same day. Our frequently asked questions answer the practical queries most people have before starting, and our clinical team is available for aftercare seven days a week once treatment begins.

Feeling frustrated that a medicine your GP mentioned months ago still isn't available through them is entirely understandable. The NHS is moving, just not at a speed that suits everyone's timeline. Speak to our prescribers to find out whether private treatment through a regulated UK pharmacy is the right option for you.